pipette
ESEspañol

Intravenous [Pyr¹]apelin-13 in Healthy Volunteers with Artificially-Induced Syndrome of Inappropriate Antidiuresis - a double-blind, randomised, placebo-controlled crossover study

Sophie Monnerat, Sven Lustenberger, Chiara Angela Bizzozero, Fiona A. Chapman, Joyce Santos de Jesus, Eszter Kustos-Toth, D. Vogt, Lorraine Bruce, Robert Little, Anthony P. Davenport, Janet J. Maguire, Julie Refardt, Martin Bidlingmaier, Neeraj Dhaun, Mirjam Christ‐Crain

Peer-reviewed journal

In the authors' words

Abstract Apelin, a hormone secreted by the posterior pituitary, antagonises arginine vasopressin in salt and water homoeostasis. Administration of apelin analogues increased urine output in hyponatremic rodent models, but corresponding human data are lacking. We therefore investigated intravenous [Pyr¹]apelin-13 in healthy participants with artificially induced syndrome of inappropriate antidiuresis. In this double-blind, randomised, placebo-controlled crossover study, 15 healthy adults (7 female; mean age, 28 years [SD, 8]) attended three study visits. Hyponatremia was induced using desmopressin, water loading, and hypotonic saline. Participants subsequently received high-dose [Pyr¹]apelin-13 (1800 nmol), low-dose [Pyr¹]apelin-13 (180 nmol), or placebo as a 3-hour infusion. The primary endpoint was cumulative urine output from infusion initiation until 1 hour after its completion. Neither apelin dose produced a clinically relevant difference in urine output compared with placebo. ClinicalTrials.gov: NCT06277336. Funded by the Swiss National Science Foundation. Registration number: NCT06277336 .

Main resultThe abstract does not state a limitation.

Appeared: Sunday, October 18. Nature Communications. Peer-reviewed journal.

DOI: 10.1038/s41467-026-78333-y